FDA
-
-
-
-
-
-
-
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations
-
-
-
-
-
-
-
Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults
-
-
-
-
-
-
-
Intra-Cellular Therapies Announces Publications Highlighting Beneficial Effects of Phosphodiesterase Type I Inhibition with Lenrispodun (ITI-214) on Cardiovascular Function in Patients with Heart Fail
-
-
-
-
-
-
-
Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression
-
-
-
-
-
-
-
Intra-Cellular Therapies (ITCI) Applies for FDA Approval of CAPLYTA for the Treatment of Bipolar Depression
-
-
-
-
-
-
-
Intra-Cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Intra-Cellular Therapies Initiates Promotional Activities for CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults
-
212,766 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All